“…Poly(lactic-co-glycolic acid) (PLGA), which is a polymer currently approved for clinical usage, hydrolyzes into its monomers (lactic and glycolic acid) and then metabolizes in vivo to be easily excreted from the body [ 48 , 49 , 50 , 51 , 52 , 58 , 59 , 60 , 61 ]. Therefore, it has been safely used to prepare intravenously injectable NP formulations [ 48 , 49 , 50 , 51 , 52 , 58 , 59 , 60 , 61 ]. In addition to their biodegradable properties, PLGA synthetic NPs are the most extensively studied of all commercially available polymeric NPs for the delivery of anti-cancer drugs due to their non-immunogenicity, microcytotoxicity, biocompatibility, high drug loading capacity, and controlled slow-release profiles [ 48 , 49 , 50 , 51 , 52 , 58 , 59 , 60 , 61 ].…”